Who makes FL058 1000mg（ IV 120min）?

FL058 1000mg（ IV 120min） is developed by Qilu Pharmaceutical Co., Ltd..

What development phase is FL058 1000mg（ IV 120min） in?

FL058 1000mg（ IV 120min） is in Phase 1.

Last reviewed 2026-04-19 · How we verify

FL058 1000mg（ IV 120min）

Qilu Pharmaceutical Co., Ltd. · Phase 1 active Small molecule

At a glance

Generic name	FL058 1000mg（ IV 120min）
Sponsor	Qilu Pharmaceutical Co., Ltd.
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety, Tolerability, Pharmacokinetics of Intravenous FL058 and Meropenem in Healthy Subjects(SAD/MAD) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FL058 1000mg（ IV 120min） CI brief — competitive landscape report
FL058 1000mg（ IV 120min） updates RSS · CI watch RSS
Qilu Pharmaceutical Co., Ltd. portfolio CI